Brightflow SAS has announces the successful completion of an oversubscribed €16.5M ($18M) in equity series A financing round.
Proceeds from the financing will fund the company’s major strategic initiatives through to early 2026, including completion of product development and first compassionate implantations.
The round was led by new investors VIVES Partners (Belgium), Majycc Innovation Santé-UI Investissement (France), BNP Paribas Development (France) and international business angels, with continued participation from the existing syndicate of GO Capital and Karista.
Brightflow’s objective is to develop a fully percutaneous long-term right ventricular (RV) mechanical circulatory support to treat end-stage heart failure in patients with severe RV dysfunction.
“This financing is testament to the strength of our technology and to our promise to create the first long-term blood pump that can be delivered safely and effectively without open-heart surgery,” said Sophie Humbert, CEO at Brightflow.
“Brightflow has a world-class founding medical team led by highly qualified executive and technical colleagues, the company has all the assets required to transform Brightflow’s innovative approach into an effective product addressing a highly unmet medical need,” said Philippe Durieux, managing partner at VIVES Partners.
“Brightflow is a perfect match for our investment strategy: high quality French innovation with the potential to yield significant improvements for patients, practitioners and payors, addressing a potentially vast global market with strong strategic interest. We are excited to support Brightflow in the next phases of its development,” said Tanguy Besson, senior associate, Majycc Innovation Santé–UI Investissement.
“As long-term investors, we are proud to be part of the syndicate that should bring Brightflow to its first in-human implantations. We are convinced that the expert team, led by seasoned medtech executives Sophie Humbert (CEO) and Lars Bredenbreuker (CTO), will transform the percutaneous approach devised by Pascal Lim into a commercial product,” said David Moreau, investment director, BNP Paribas Development.
“Following our seed investment in 2021, we are proud to announce this new round which enables Brightflow to continue the development of its innovative medical device up to the first compassionate cases,” said Leila Nicolas, partner at GO Capital and Baudouin Hue, partner at Karista.
“We believe the unique design of our blood pump solution will significantly improve the quality of life of many patients,” said Pascal Lim, founder and president of Brightflow.
